Search Results

Intel Labs is showcasing some of its most significant and industry-first AI innovations at NeurIPS 2023 — the leading global event for developers, researchers, and academic professionals focused on AI and computer-vision technologies.

Renovaro Biosciences Inc., a biotechnology corporation focusing on cell, gene, and immunotherapy, has announced that Avram Miller will join its Board of Directors.

Contract Medical and Commercial Organization, Amplity Health has released a revolutionary AI-driven next best action solution that provides pharmaceutical and biopharmaceutical companies with an entirely new order of field insights that can be acted upon within the earliest days of a drug’s release.

SiPhox Health, the leader in building the next generation of lab-grade home health testing with silicon photonics, raised $27 million in funding including a $10M Seed financing and a $17M Series A round.

Positron Corporation is pleased to announce that it has ordered five NeuSight PET-CT 64 slice scanners from cooperative partner Neusoft Medical Systems’ subsidiary, Shenyang Intelligent Neuclear Medical Technology Co.

Atrion Corporation (NASDAQ: ATRI), a developer and manufacturer of products primarily for medical applications, today announced that it has entered into an agreement and plan of merger with Nordson Corporation pursuant to which Nordson will acquire Atrion for $460 per share in cash, representing a total equity value of approximately $815 million.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company, announced a corporate update on recent developments.

Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”) today announced financial results and recent corporate highlights for the first quarter ended March 31, 2024.

Positron Corporation (“Positron” or the “Company”) (OTC: POSC) is pleased to announce it has entered an agreement to acquire the FDA 510(k) for the NeuSight PET-CT from its cooperative partner Neusoft Medical Systems’ subsidiary, Shenyang Intelligent Neuclear Medical Technology Co.

FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to provide the following corporate update.